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CLINICAL INVESTIGATION
Role of EDRF (nitric oxide) in diabetic renal hyperfiltration
NORMAN BANK and HAGOP S. AYNEDJIAN
Renal Division, Department of Medicine, Montefiore Medical Center, and the Albert Einstein College of Medicine, Bronx, New York, USA
Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. In order to
study the role of EDRF in diabetic hyperfiltration, the concentrations of
NO/NO, the stable products of nitric oxide (NO), were measured in
arterial plasma, urine, and renal venous blood in streptozotocin diabetic
rats and normal control rats. In additional experiments, the renal
hemodynamic and blood pressure responses to graded doses of an
inhibitor of NO synthesis (Nitro-L-arginine; NLA) were measured. We
found that plasma and urinary levels of NO/NO are significantly
higher in STZ diabetic rats (10 to 15 days) than in normal rats. Renal
blood flow and GFR fell comparably in diabetic and normal rats in
response to NLA infusion, although the absolute levels of RBF and
GFR remained significantly higher in the diabetic rats at all doses of the
inhibitor. Mean arterial blood pressure (MAP) rose in response to NLA
administration, but the increase in the diabetic rats was significantly
blunted as compared with the normal rats. Similarly, renal vascular
resistance (RVR) increased less in the diabetic than in the normal rats
at comparable doses of NLA. The blunted vasoconstrictor responses to
NLA were accompanied by a smaller reduction in the levels of
NO/NO in the urine of the diabetic versus the normal rats. These
findings suggest that NO synthesis is increased in diabetic rats mani-
festing hyperfiltration and are consistent with the view that excess NO
synthesis contributes to renal hyperfiltration.
A number of studies have shown that a variety of abnormal-
ities in the function and biochemistry of the endothelium occur
in diabetic animals [1—3]. Synthesis of some prostaglandins is
increased [4—8], causally related to elevated levels of blood
glucose [9—12], whereas production of prostacyclin is reduced
[4]. Takeda et al [13] reported a twofold increase in the release
of endothelin 1 (ET-1) from the mesenteric arteries of diabetic
rats, as well as increased circulating levels of ET- 1. Von
Willebrand factor, also synthesized by endothelial cells [14], is
elevated in the plasma of patients and animals with diabetes
[15—17]. In addition, a number of studies have shown that
vascular relaxation in response to agents which release EDRF
(nitric oxide, NO) from the endothelium is impaired in diabetic
animals [18—21], and it was postulated that diabetes interferes
with synthesis or release of nitric oxide by endothelial cells.
In the present study, we examined the role of EDRF in
contributing to the increased renal blood flow and GFR of
streptozotocin-diabetic rats. As an index of synthesis of NO,
we measured plasma, urine, and renal vein concentrations of
NO/NO, the stable metabolic products of NO, as well as the
renal hemodynamic effects of acute inhibition of NO synthesis.
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The results indicate that arterial plasma levels of NO/NO are
elevated in diabetic rats, and the excretion of these anions in the
urine is markedly increased. Renal vascular resistance (RVR)
and mean arterial blood pressure (MAP) rose in response to
inhibition of nitric oxide synthase (NOS), but the increases
were blunted as compared with normal rats. These observations
provide evidence that NO synthesis is increased in diabetes,
presumably by the vascular endothelium. Over-production of
NO may play a significant role in the hyperfiltration of early
diabetes, and perhaps the increase in regional blood flow to
other organs.
Methods
Experiments were carried out in male Sprague-Dawley rats.
Diabetes was induced by i.v. injection of streptozotocin in
acetate, 60 mg/kg body wt. Development of diabetes was
confirmed in each animal by urinary dipstick test for glucose,
and by measurement of blood glucose on the day of renal
hemodynamic study. The animals were housed in individual
cages, given free access to an unlimited supply of drinking
water and fed a pre-weighed ration of regular rat pellet diet (25
g/day). Insulin was not given. All experiments were carried out
10 to 15 days after the onset of diabetes. Normal rats served as
controls, and were matched to the body weights of the diabetic
rats after diabetes had been present for 10 to 15 days.
Measurements of NO + NO
Group 1. In six normal and six diabetic rats, anesthesia was
induced by i.p. injection of mactin, 100 mg/kg body wt. A
jugular vein was catheterized with PE 50 tubing for infusion of
'4C-inulin (New England Nuclear Co., Boston, Massachusetts,
USA) in Ringer's solution. The infusion rate was 2 mllhr/lOO g
body wt. Priming and sustaining doses of 14C-inulin were added
to the i.v. infusion. The left kidney was exposed through a small
midline abdominal incision, extended laterally. The left ureter
was cannulated with PE 50 tubing for timed urine collections.
Renal blood flow to the left kidney was measured continuously
with an ultrasonic flow probe positioned around the main left
renal artery, as previously described [22]. A carotid artery was
cannulated with PE 50 tubing for continuous monitoring of
mean arterial blood pressure (MAP), using previously described
equipment [22], and for periodic sampling of arterial blood for
measurements of 14C-inulin. Arterial blood was collected from
the abdominal aorta and renal venous blood before sacrifice, for
measurement of NO/NO. Glomerular filtration rate (GFR) of
the left kidney was calculated from the urine/plasma '4C-inulin
ratio x urine flow rate.
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Table 1. Renal hemodynamics
w
g
RBF RPF GFR
FFmi/mm
Normal rats (6) 310 9 8.06 0.11 4.57 0.06 1.20 0.08 0.268 0.008
Diabetic rats (6) 297 4 9.50 0.09 5.51 0.07 1.62 0.10 0.290 0.007
P NS <0.001 <0.001 <0.01 NS
Data are for the left kidney, expressed as mean SEM. NS = P value > 0.05.
The stable metabolic products of nitric oxide, NO and NO
were measured in urine and in deproteinated plasma by means
of the brucine method [23]. A 2:1 dilution of NOV-free concen-
trated H2S04 (Ricca Chem. Co., Arlington, Texas, USA) was
prepared, to which was added 60 mg% strychnine (chemically
related to brucine). This stock solution was prepared monthly,
and stored at 5°C. NO in urine and plasma was oxidized to
NO by titration with 0.3% KMNO4, until a slight purple color
was evident. After 30 minutes, the sample was titrated with I M
sodium bisulfite to decolorize. Four ml of the strychnine
solution was then added to 1 ml of unknowns or standards. The
mixture was heated for 10 minutes in a boiling hot water bath,
and then transferred to an ice bath for 20 minutes. The resulting
sulfur-yellow color was read on a spectrophotometer at 410 m.
Standard curves were established with NaNO3, prepared by the
same steps used for the unknowns. In the case of plasma
samples, protein was precipitated with TCA (10% wt/vol). All
samples were measured in duplicate. The brucine method is
sensitive to 0.01 ppm [23].
Inhibition of NO with nitro-L-arginine (NLA)
Group 2. In seven normal and seven STZ-diabetic rats, renal
hemodynamic measurements were carried out during step-wise
increasing doses of nitro-L-arginine (Aldrich Chem Co., St.
Louis, Missouri, USA) administered intra-arterially via a cath-
eter threaded from a femoral artery into the aorta above the
renal arteries. The intra-aortic route was used in order to
maximize delivery of each dose of the drug to the kidneys. The
animals were anesthetized with mactin, 10 mg!lOO g body
weight and placed on a heated animal table. A jugular vein was
cannulated with PE 50 tubing for infusion of 14C-inulin in
Ringer's solution, delivered at 1 mllhr/l00 g body wt. A carotid
artery was cannulated with PE 50 tubing for continuous moni-
toring of MAP and obtaining blood samples for '4C-inulin
measurements, as in the Group 1 experiments. RBF of the left
kidney was measured with the ultrasonic flow probe. The left
ureter was catheterized with PE 50 tubing for timed urine
collections.
In each animal, there was a control period without infusion of
nitro-L-arginine (NLA) followed by periods with infusion of
different doses of NLA. The doses used were 1.1, 2.3, 3.4, and
4.6 M given over 10 minutes. Urine collections were obtained
during each experimental period, and a 15 minute interval was
allowed for stabilization of MAP after each dose of NLA.
Arterial blood samples were obtained before and after each
urine collection for measurement of 14C-inulin.
Glomerular filtration rate of the left kidney was calculated
from the expression GFR = U/P,11 x V where U/P11rnim is the
urine/plasma '4C-inulin concentration ratio, and V is the urine
flow rate in mI/mm. Renal vascular resistance of the left kidney
was calculated from the expression
MAP -3
RYR =
RBF
A value of 3 mm Hg for renal venous pressure was used in the
calculation of the pressure gradient across the renal vascular
bed. In analyzing the response to NLA, the hemodynamic data
were plotted against cumulative doses of NLA, since blood
pressure responses to inhibition of NO are prolonged.
Group 3. In three normal and three diabetic rats, prepared in
the same way described above, urine was collected for NO/
NO measurement during a control period, followed by intra-
aortic infusion of NLA at two successive doses of 3.4 iM and
4.6 ILM. Urine collections were obtained at each dose, and MAP
and GFR were measured during all three periods. These exper-
iments were designed to assess the effect of inhibition of NO
synthesis on NO/NO excretion in normal and diabetic rats.
Statistical analysis
Data are expressed as mean SEM. Differences between
normal control and diabetic rats were analyzed by Student's
unpaired t-test. Hemodynamic responses to various doses of
NLA were analyzed by linear regression, using least squares
method. In addition, the mean SEM hemodynamic values
obtained with each dose of NLA were calculated, and the
differences between normal versus diabetic rats were deter-
mined by Student's unpaired (-test.
Results
Plasma and urinary NO/NO
Renal hemodynamic and body weight data are shown in
Table 1. There was no significant difference in body weight of
the two groups of rats at the time of study. GFR and RBF were
significantly elevated in the diabetic rats. Filtration fraction was
numerically higher in the diabetic animals, but the difference
did not reach statistical significance. Measurements of arterial,
renal vein and urinary NO/NO are shown in Table 2. It was
evident that arterial plasma levels of NO/NO were signifi-
cantly higher in the diabetic than in the normal rats. Because of
this and the higher GFR, filtered NO/NO was almost twice as
high in the diabetic rats. Urinary excretion rate of these anions
was approximately fourfold greater in the diabetic versus the
normal rats. These observations imply that production of NO
was significantly increased in the diabetic animals. This cannot
be attributed to differences in dietary source of L-arginine, the
precursor of NO, since the diabetic and normal rats were fed
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Table 2. Plasma levels and renal handling of NO/NO in normal and diabetic rats
NO/NO3
/LM/flI
Filtered
NO/NO
Excreted
NO/NO
Excreted
fraction
&Y
A
%jiM/mm
Normal rats (6)
Diabetic rats (6)
P
0.198 0.003
0.279 0.018
<0.01
0.237 0.005
0.433 0.044
<0.01
0.033 0.004
0.156 0,016
<0.001
13.9 1.7
34.8 2.4
<0.01
2.67 0.92
5.80 0.74
<0.05
Data reported as mean SEM. Number in parenthesis is the number of animals. Statistical analysis by Student's unpaired t-test.
Delivered
to kidney
jiM/mm
Calculated
extraction
Measured
extraction Estimated
productiona
/J.M/mifl%
Normal rats 0,905 3.8 2.67 0.010
Diabetic rats 1.537 10 5.80 0.065
the same pre-weighed ration of food daily, and all animals
consumed the entire ration. The plasma and urinary excretion
of NO/NO in the normal rats were higher than values
reported by Shultz and Raij [24], who used the Griese method.
The brucine method used in the present study oxidizes NO —
NO in solution and measures total NOV. The Griese method
on the other hand reduces nitrates to nitrites by incubating
samples with nitrate reductase enzyme grown from E. co/i
under anaerobic conditions. In addition, in the study by Shultz
and Raij, urine was collected from conscious rats, whereas in
the present study the animals were under general anesthesia
and had undergone vascular catheterization and abdominal
surgery. It is possible that the higher values obtained in the
present study as compared to those reported by Shultz et al are
due to these methodologic differences.
It is clear from the data in normal rats shown in Table 2, that
urinary excretion of NO/NO was only 14% of the calculated
ifitered amount, assuming that these small anions are freely
filtered by the glomerulus. Since the filtration fraction was 0.27
(Table 1), the renal extraction of NO/NO should have been
about 3.8% (0.14 x 0.27) if NO/NO were not being generated
by the kidney. The fact that the measured renal extraction was
only 2.67% suggests that the normal kidney synthesizes small
amounts of NO/NO which enters the renal venous blood.
The calculated production of NO/NO by the kidney is shown
in Table 3. The difference between the measured and calculated
extraction is 1.1%. Multiplying 1.1% by the amount of NO/
NO delivered to the kidney via the arterial blood yields an
estimated renal production rate of 0.0 10 JiM/mm NO7NO.
That the rat kidney does produce EDRF has previously been
deduced from physiologic response experiments carried out on
isolated perfused organs [25], and from direct measurements in
rat glomerular mesangial cells [261. With regard to the diabetic
rats, when we apply the same estimation of renal extraction of
NO/NO, a filtration fraction of 0.29 and an excreted fraction
of 35% yields a renal extraction of 10% if the kidney cells were
not synthesizing any NO/NO. The fact that the measured
A-V/A value was only 5.8% suggests that 4.2% of the delivered
NO/NO was being produced by the diabetic kidneys. The
calculated amount, shown in Table 3, suggests that the diabetic
kidneys were producing approximately six times more NO/
NO than the normal kidneys. Thus, renal production of
NO/NO appeared to contribute to the higher arterial blood
levels found in the diabetic rats.
Inhibition of NO synthesis
The results of acute inhibition of NO by intra-aortic infusion
of NLA are shown in Figures 1 to 4. The effect on MAP of
various doses of NLA is shown in Figure 1. In all cases in which
multiple doses were administered to the same animal, the
cumulative dose was used in the analysis, since the effect of
EDRF inhibition is relatively long-lasting. The MAP at each
dose of NLA was higher in the normal versus the diabetic rats,
but the differences were not statistically significant except at the
highest dose. However, the slopes of the linear regression lines
were significantly different. The correlation coefficient was 0.91
in the normal rats and 0.72 in the diabetics. The equation for the
normal rats was y = 118.7 + 18.7x, and for the diabetic rats was
y = 118.8 + 10.9x. The slopes of the two lines were significantly
different (18.6 vs. 10.9, P < 0.01). The diabetic rats thus
exhibited a somewhat blunted rise in MAP in response to the
inhibitor of NO synthesis.
The effects of EDRF inhibition on RBF and GFR are shown
in Figures 2 and 3. The absolute levels of RBF and GFR were
significantly higher in the diabetics versus the normal controls,
and remained higher at each dose of NLA (P < 0.05). As can be
seen, there was a progressive fall in both RBF and GFR with
Table 3. Estimated renal production of NO/NO
a The estimated production of NO/NO is the difference between
calculated and measured renal extraction, multiplied by the amount
delivered to the kidney via arterial blood
160
150
E 140
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110
Nitro-L-arginine, tM
Fig. 1. Effect o,f nitro-L-argmnine infusion on MAP. Symbols are: (•)
normal and (0) diabetic, Each point is mean of 2 to 4 measurements.
The vertical lines represent SEM. * P < 0.05, diabetic vs. normal. The
linear regression lines were calculated by least squares.
0 2 4 6 8 10
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doses of NLA between 2.2 and 8 prsi. In both the normal and
diabetic rats, the fall in RBF followed a straight line relation-
ship, the correlation coefficients being 0.91 for the normals and
0.94 for the diabetics. The equation for the normal rats was y =
6.91 — 2.08x, and for the diabetic rats was y = 8.57 — 2.18x.
There was no statistical difference in the slopes between the
normals and diabetics (—2.8 vs. —2.18). GFR was also higher in
the diabetic versus normal rats at all levels of inhibition of NO
(P < 0.05). The decline in GFR in response to NLA infusion
followed the same pattern as RBF, and again there was no
significant difference in the slopes of the lines (—0.34 vs.
—0.25). The equation for the normal rats was y = 1.08 — 0.34x
and for the diabetic rats was y = 1.37 — 0.25x.
In spite of the similar responses of RBF and GFR to NO
inhibition in the two groups of animals, the rise in renal vascular
resistance (RVR) was significantly blunted in the diabetic rats.
These data are shown in Figure 4, where it can be seen that
RVR was significantly lower in diabetic rats than in the nor-
mals. In both groups, RVR rose with increasing doses of NLA,
but the values remained higher in the normals than in the
diabetics (P < 0.05). The slope of the rise was significantly less
in the diabetics versus the normals (7.99 vs. 14.25, P < 0.01).
Discussion
The major finding of the present study is that plasma and
urinary excretion levels of NO/NO are considerably higher
in IDDM rats of 10 to 15 days duration than in normal rats.
Since NO/NO are the stable oxidation products of NO,
which has a very short half-life, NO/NO can be taken as an
index of NO production. It is reasonable to assume that the
higher blood levels are the result of a generalized increase in
synthesis of NO throughout the body. The blood samples for
these measurements were collected from the abdominal aorta,
and therefore presumably reflects concentrations of NO/NO
throughout the central arterial circulation, although regional
differences in various organs may exist. Because of the higher
blood levels and the higher GFR in the diabetic rats, the filtered
load of NO/NO was approximately twofold greater in the
diabetic versus normal rats, and urinary excretion was fivefold
greater (Table 2). The kidney is therefore a major organ for
excretion of NO/NO in both normal and diabetic rats.
Measurements of the renal A-V gradient of NO/NO suggest
that the kidney also produces NO and releases NO/NO into
the renal venous blood, and that renal production of NO/NO
in the diabetic rats was approximately sixfold greater than in the
normal rats.
It is well established that EDRF (NO) synthesized by endo-
thelial cells is released from these cells into the contraluminal
space as well as into the blood stream, although the relative
0 2 4 6 8 10 0 2 4 6 8 10
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Fig. 4. Effect of NLA on renal vascular resistance. Symbols are: (•)
Fig. 2. Effect of NLA on renal blood flow. Symbols are: (•) normal; normal and (0) diabetic. Data are for the left kidney.(0) diabetic. Data are for the left kidney. Statistical analysis as in Fig.
1.45 The equation for the normal rats was y = 16.6 + l4.25x, r =
0.92, and for the diabetic rats was y = 12.98 + 7.99x, r 0.96.
1.25 Table 4 shows urinary excretion of NO/NO in an addi-
1 05 tional group of normal and diabetic rats administered two doses
of NLA. It can be seen that at the higher dose of 8 tM of NLA,
E 0.85 GFR fell by 59% in the normal rats but only by 11% in the
diabetics (P < 0.01). MAP rose by 49% in the normals versus
0.65 only 10% in the diabetics. Urinary NO/NO fell by 54% in the
0 45 normal rats, whereas it fell by only 14% in the diabetic rats.Thus, in the presence of the same doses of NLA, there were
0.25 blunted responses of MAP and GFR in the diabetic rats, and
0 2 4 6 8 10 this was associated with continuing high urinary excretion rates
of NO/NO.
Nitro-L-arginirie, JIM
Fig. 3. Effect of NLA on glomerular filtration rate. Symbols are: (•)
normal and (0) diabetic. Data are for the left kidney.
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Table 4. Effect of inhibition of nitric oxide synthase (NOS) on NO/NO excretion
Dose NLA 0 3.4 rM 8 ILM
GFR mi/mm Normal rats
Diabetic rats
1.16 0.04
1.49 0.06
0.81 0.09
1.36 0.05
0,47 0.08
1.33 0.04
P <0.02 <0.05 <0.02
MAP mm Hg Normal rats
Diabetic rats
126 2.8
122 2.9
136 1.4
125 1.6
139 2.1
127 1.4
P NS <0.02 <0.02
NO/NO /IM/min Normal rats
Diabetic rats
0.022 0.001
0.138 0.0005
0.012 0.002
0.122 0.006
0.010 0.002
0.119 0.01
P <0.001 <0.001 <0.001
NLA infused into abdominal aorta above the renal arteries. GFR and NO/NO excretion data are for the left kidney. P values were calculated
by unpaired i-test.
distribution and the factors determining the directional diffusion
of NO are unknown [27]. Since NO is a highly diffusible
substance, it seems likely that the direction of its movement out
of cells depends on concentration gradients and local conditions
affecting its oxidation to NO2 and NO3. Such reasoning sug-
gests that a major fraction of NO synthesized from L-arginine
by endothelial cells diffuses into the blood stream. This view is
supported by the fact that an assay system for evaluating NO
synthesis, which utilizes two blood vessels in series connected
by luminal flow, demonstrates reactions of the downstream
vessel to agonists which release NO from the upstream vessel
[281. This requires intraluminal release of NO by the upstream
vessel. The finding of elevated arterial blood concentrations of
NO/NO in diabetic rats is thus consistent with the assump-
tion that there is increased synthesis of NO by diabetic endo-
thelial cells. The enzyme responsible for NO synthesis from
L-arginine, nitric oxide synthase (NOS), exists in three iso-
forms, calcium dependent constitutive forms and a calcium
calmodulin-independent inducible isoform (Type II) [29]. En-
dotoxin for example has been shown to cause induction of NOS
[25], and results in marked increases in plasma NO in experi-
mental animals [25]. Whether similar enzyme induction occurs
in diabetes, or whether increased amounts of L-arginine are
available for NO synthesis due to the catabolic state of the
diabetic rats require further studies. Either mechanism could
result in elevated levels of NO production.
To study the functional significance of the increase in EDRF,
we infused the competitive inhibitor of NO synthesis, NLA,
into the aorta. As shown in Figure 1, MAP increased linearly in
both the normal and diabetic rats with progressive doses of
NLA. Although a statistical difference in MAP resulted only at
the highest dose of NLA used, the slope of the rise was
significantly lower in the diabetic rats vs. the normal rats.
Similarly, renal vascular resistance (RVR) (Fig. 4) increased in
both groups of rats during NLA infusion, but the increase was
significantly blunted in the diabetics. As shown in the Group 3
experiments (Table 4), urinary excretion of NO/NO at two
different doses of NLA continued to be much higher in the
diabetic rats than in the normals. Thus, NLA appeared to
inhibit NO synthesis less in the diabetic rats than in the
normals. This might be due to the presence of inducible NOS in
the diabetic rats versus constitutive NOS in the controls, and
the possibility that NLA is a less potent inhibitor of inducible
NOS. Alternatively, high levels of endogenous L-arginine in the
diabetic rats could counteract the inhibitory effect of NLA. In
either case, these observations are consistent with the view that
excess EDRF played a significant role in contributing to re-
duced vascular tone in diabetic rats, as manifested by both an
impaired rise in MAP and RVR associated with continuing high
levels of NO/NO in the urine.
Although our observations are consistent with this interpre-
tation, several alternative mechanisms are possible. Vasocon-
striction that occurs when EDRF is inhibited is due to a shift in
the balance of vasoconstrictors/vasodilators acting on vascular
smooth muscle cells [30, 31]. Thus, the endogenous levels of
angiotensin II, endothelin, norepinephrine and the density of
their respective receptors might account for the lesser vasocon-
strictor response to EDRF inhibition in diabetic animals [1]. In
addition, it is possible that an intrinsic defect in vascular
smooth muscle cell contractility may be responsible for the
findings, since endothelium-denuded vessels from diabetic ani-
mals demonstrate impaired contraction when depolarized by
elevated extracellular KC1 [1]. It seems unlikely that the in-
creased arterial blood levels of NO/NO can be secondary to
the increase in renal blood flow, even though flow velocity has
been shown to elevate NO/NO release in isolated vascular
preparations [32—34]. If increased RBF were the primary event
and the elevated plasma NO/NO were secondary, one would
expect little or no reduction in RBF when NO synthesis was
inhibited by NLA, rather than the straight line relationship
which we observed. Finally, it is unlikely that a lack of
vasoconstrictor prostanoids can account for the findings, since
vascular TxA2 and PGH2 synthesis has been found to be
increased in the presence of hyperglycemia [7, 12, 35]. Thus,
the impaired vasoconstriction in response to inhibition of
EDRF in the diabetic rats might be caused by several different
mechanisms. However, the demonstrated increase in the blood
and urine levels of the metabolic products of NO, and the
parallel fall in RBF and GFR in the diabetics versus the normal
controls with NLA infusion supports the view that enhanced
synthesis of EDRF plays an important role in the renal hyper-
emia of the diabetic rats.
Several previous studies have suggested that synthesis or
release of EDRF is impaired in blood vessels obtained from
diabetic animals, or in normal blood vessels exposed to high
glucose concentrations. Meraji et al [19] found that acetyicho-
line-induced relaxation of pre-constricted aortae from BB dia-
betic rats was diminished as compared with normal aortae.
Oyama et at [18] studied aortic rings from STZ-diabetic and
normal rats, pre-contracted with norepinephrine. They found
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relaxation in response to acetyicholine or histamine to be
attenuated in the diabetic aortae. Bucala, Tracey and Cerami
[36] found that advanced glycosylation products prepared in
vitro quench NO in solution. In the same study, they also found
that the fall in MAP in response to injected acetyicholine was
less in diabetic rats than in normal rats, a difference which was
improved by administration of aminoguanidine to inhibit in vivo
glycosylation. This defect in systemic vasodilation appeared
after one month of diabetes and was not present at two weeks,
making it unlikely that advanced glycosylation products were
playing a role in our animals. In contrast to the above-men-
tioned studies, Bhardwaj and Moore [37] found an increased
renal vasodilatory response to acetyicholine in diabetic rats.
Interpretation of pharmacologic responses to acetyicholine, or
to similar endothelial-dependent agonists is difficult, because
these agents release a variety of substances from the endothe-
hum, including NO, TxA2, PGF2 and PGH2 [12]. Moreover,
diabetic blood vessels or normal blood vessels incubated in high
glucose media, synthesize vasoconstrictor prostanoids in in-
creased amounts, and these can counteract the expected va-
sodilatory effect of NO [351. Thus, a blunted response to
acetylcholine in diabetic animals cannot be taken as unequivo-
cal evidence of impaired synthesis or activity of NO. In
addition, a more rapid oxidation of NO to non-reactive species
after it is released from the endothelial cells may result in a
diminished vasodilating response [28]. This might occur via
superoxide anion, which is thought to be increased in diabetes
[38—40]. Tesfamariam and Cohen [401 have postulated that
increased superoxide anion contributes to the impaired relax-
ation response to acetylcholine by diabetic blood vessels, and
Hattori et al [41] demonstrated that superoxide dismutase
restores endothelial-dependent relaxation of the aorta of dia-
betic rats. Thus, in diabetic rats, there appears to be increased
NO production, as well as increased oxidation of NO by
superoxide anion. The balance of these two processes presum-
ably determines the net effect of NO on vascular tone invivo.
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